CURRICULUM VITAE

Martin Zenke, PhD Professor of Cell Biology

RWTH Aachen University Hospital Institute of Department of Cell Biology Pauwelsstr. 30 52074 Aachen, Germany

Helmholtz Institute for Biomedical Engineering Pauwelsstr. 20 52074 Aachen, Germany www.molcell.de e-mail: [email protected]

Academic Curriculum: 1982 PhD, Faculty of Biology, Ruprecht-Karls-University, HEIDELBERG, Germany.

1982-1985 Postdoctoral fellow, Université Louis Pasteur, Laboratoire de Genetique Moleculaire des Eucaryotes (LGME), STRASBOURG, France.

1985-1988 EMBL fellow, Differentiation Programme, European Molecular Biology Laboratory (EMBL), HEIDELBERG, Germany.

1988-1995 Junior Scientist, Institute of Molecular Pathology (IMP), VIENNA, Austria.

1995-2003 Research Group Leader, Max-Delbrück-Center for Molecular (MDC), BERLIN, Germany. since 2003 Professor of Cell Biology and Chairman, Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School and Helmholtz Institute for Biomedical Engineering, Rheinisch-Westfälische Technische Hochschule (RWTH), AACHEN, Germany.

Scientific Awards: since 2008 Member of "Central Ethics Committee for Research", Federal Ministry of Education and Research (BMBF) and Federal Ministry of Health (BMG), Berlin, Germany. since 2013 Member of “Gene Technology Monitoring Program” of Berlin-Brandenburg Academy of Sciences and Humanities, Berlin, Germany.

Research Interests: Hematopoietic stem cells, antigen presenting dendritic cells, reprogramming, ES cell and iPS cells, gene regulation, chromatin, biomaterials and .

Publications:

Seré, K., Baek, J.-H., Ober-Blöbaum, J., Müller-Newen, G., Tacke, F., Yokota, Y., Zenke, M.*, and Hieronymus, T.* (2012) *Corresponding authors. Two distinct types of Langerhans cells populate the skin during steady state and inflammation. Immunity 37, 905-919. Kim, J. B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Araúzo-Bravo, M. J., Ruau, D., Han, D. W., Zenke, M. and Schöler, H. R. (2008). Pluripotent stem cells derived from adult neural stem cells by reprogramming with two factors. Nature 454, 646-650. Hacker, C., Kirsch, R. D., Ju, X.-S., Hieronymus, T., Gust, T. C., Kuhl, C., Jorgas, T., Kurz, S. M., Rose-John, S., Yokota, Y. and Zenke, M. (2003). Transcriptional profiling identifies Id2 function in dendritic cell development. Nature Immunology 4, 380-386. Boehmelt, G., Madruga, J., Dörfler, P., Briegel, K., Schwarz, H., Enrietto, P. and Zenke, M. (1995). Dendritic cell progenitor is transformed by a conditional v-rel estrogen receptor fusion protein v-relER. Cell 80, 341- 352.

2

Abstract:

Hematopoietic Stem Cells and Cellular Engineering

Martin Zenke, Institute of Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Hospital, Pauwelsstr. 30 and Helmholtz Institute for Biomedical Engineering, Pauwelsstr. 20, 52074 Aachen, Germany. e-mail: [email protected], http://www.molcell.de.

Hematopoietic stem cells (HSC) give rise to all cells in peripheral blood and blood-borne lymphoid tissues. I will present results on HSC differentiation into dendritic cells (DC) and how HSC differentiation is perturbed in leukemia.

DC are professional antigen presenting cells and central in induction of tolerance and immunity. DC occur in various anatomical locations and different DC subsets have been identified. We use in vitro cultur systems, profiling, chromatin immunoprecipitation and knock-out mouse models to decipher DC development on the molcular level. Our studies reveal a molecular circuitry of a set of trancription factors that determines (i) HSC commitment towards DC and (ii) DC identity and function. These results highlight that DC represent a hematopoietic lineage in their own right.

In leukemia, HSC differentiation is perturbed and stem/progenitor cells aberrantly proliferate at the expense of differentiated cells. Recent advances in therapy of chronic myeloid leukemia (CML) demonstrate the impact of molecular medicine for targeted therapy. The identification of the CML specific bcr/abl lesion and its enzymatic activity allowed development of drugs (such as Imatinib) that can control CML. We generate induced pluripotent stem cells (iPS cells) of leukemia with JAK2 and KIT mutations to develop in vitro disease models and screening systems for drug development to treat leukemia.

To meet the need of obtaining large numbers of iPS cells for disease modeling and drug development, a consortium of experts in engineering sciences and stem cell biology develops an automatic production unit for iPS cells (www.stemcellfactory.de).